Myocardial infarction in a 35-year-old man with homocysteinemia, high plasminogen activator inhibitor activity, and resistance to activated protein C

Metabolism: Clinical and Experimental

Volumn 46, Issue 12, 1997, Pages 1470-1472

  Glueck, C J ^a   Fontaine, Robert N ^b   Gupta, Arun ^b   Alasmi, Mahmood ^b  

^a JEWISH HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; BLOOD CLOTTING FACTOR 5 LEIDEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; PLASMINOGEN ACTIVATOR INHIBITOR; TRIACYLGLYCEROL;

ACUTE HEART INFARCTION; ADULT; ARTICLE; ATHEROSCLEROTIC PLAQUE; CASE REPORT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FIBRINOLYSIS; GENE MUTATION; HOMOCYSTINURIA; HUMAN; HYPERLIPIDEMIA; MALE; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; RISK FACTOR; THROMBOSIS;

EID: 0031464710     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90150-5     Document Type: Article

References (23)

1. Sprengers ED, Kluft C: Plasminogen activator inhibitors. Blood 69:381-387, 1987
2. ECAT Angina Pectoris Study Group: ECAT Angina Pectoris Study: Baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 14:8-17, 1993
3. Hamsten A, de Faire U, Walldius G, et al: Plasminogen activator inhibitor in plasma: Risk for recurrent myocardial infarction. Lancet 2:3-9, 1987
4. Glueck CJ, Freiberg R, Tracy T, et al: Thrombophilia and hypofibrinolysis. Pathophysiologies of osteonecrosis. Clin Orthop 334: 43-56, 1997
5. Eriksson P, Kallin B, van't Hooft FM, et al: Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 92:1851-1855, 1995
6. Ossei-Gerning N, Mansfield MW, Stickland MH, et al: Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. Arterioscler Thromb Vasc Biol 17:33-37, 1997
7. Malinow MR: Homocyst(e)ine and arterial occlusive diseases. J Intern Med 236:603-617, 1994
8. Glueck CJ, Shaw P, Lang J, et al: Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 75:132-136, 1995
9. Kluijtmans LA, van den Heuvel L, Boers GHJ, et al: Molecular genetic analysis in mild hyperhomocysteinemia: A common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 58:35-41, 1996
10. Ridker PM, Hennekens CH, Lindpaintner K, et al: Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 332:912-917, 1995
11. Glueck CJ, Brandt G, Gruppo R, et al: Resistance to activated protein C, Legg-Perthes disease, and thrombosis. Clin Orthop 338:139-152, 1997
12. Bontempo FA, Hassett AC, Faruki H, et al: The factor V Leiden mutation: Spectrum of thrombotic events and laboratory evaluation. J Vasc Surg 25:271-275, 1997
13. Nowak-Gottl U, Koch HG, Aschka J, et al: Resistance to activated protein C (APCR) in children with venous or arterial thromboembolism. Br J Haematol 92:992-998, 1996
14. Weiss EJ, Bray PF, Tayback M, et al: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 334:1090-1094, 1996
15. Skogen B, Bellissimo DB, Hessner MJ, et al: Rapid determination of platelet alloantigen genotypes by polymerase chain reaction using allele-specific primers. Transfusion 34:955-960, 1994
16. Glueck CJ, Glueck HI, Tracy T, et al: Relationships between lipoprotein (a), lipids, apolipoproteins, basal and stimulated fibrinolytic regulators and D-dimer. Metabolism 42:236-246, 1993
17. Gruppo R, Glueck CJ, McMahon RE, et al: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. Pathophysiology of osteonecrosis of the jaw. J Lab Clin Med 127:481-488, 1996
18. Glueck CJ, Crawford A, Roy D, et al: Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg Perthes disease. J Bone Joint Surg 78A:3-13, 1996
19. Fontaine RN, Gupta A, Glueck CJ: 4G/4G homozygosity in the plasminogen-activator inhibitor gene promotor in patients with familial high plasminogen activator inhibitor. J Invest Med 45:261A, 1997 (abstr)
20. Smith EB: Fibrinogen, fibrin, and fibrin degradation products in relation to atherosclerosis. Clin Haematol 15:355-370, 1986
21. Glueck CJ, Lang JE: Lipoprotein metabolism in the elderly, in Abrams WB, Beers MH, Berkow RB (eds): The Merck Manual of Geriatrics. Rahway, NJ, Merck, 1995, pp 1023-1052
22. Mandel H, Brenner B, Berant M, et al: Coexistence of hereditary homocystinuria and factor V Leiden - Effect on thrombosis. N Engl J Med 334:763-768, 1996
23. Davies MJ, Thomas A: Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. New Engl J Med 310:1137-1140, 1984